Clinical Trials
12 trialsNCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT02867592 2026-05-27
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05263050 2026-05-22
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02721732 2026-01-29
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07167329 2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2 Recruiting
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT02273752 2017-02-03
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Emory University
Phase 2 Terminated
NCT00923481 2015-09-30
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00637637 2013-08-12
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00091182 2013-06-05
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
National Cancer Institute (NCI)
Phase 2 Completed
NCT00264433 2007-08-06
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
Adherex Technologies, Inc.
Phase 2 Completed